Allergen Peptide SIgnatureS in allergic vs tolerant individuals (APSIS): paving the way for novel personalized medicine approaches to diagnose and cure food allergies

Project Details


Food allergy emerged over the past decade as an important public health problem, in a second wave of the 'allergy epidemic' succeeding the first respiratory epidemic. Highest rates, estimated up to 8%, are reported in the pediatric population. Clinical phenotypes of food-allergic patients are highly diverse - with allergens threshold doses varying from low to high, cross-reactions from limited to broad and symptoms from mild to severe. Two unmet clinical needs apply for food allergies, i) in-vitro diagnosis determines allergic sensitization but fails to predict clinical phenotypes and ii) management relies on avoidance and symptomatic medication, without validated therapeutic options.
Potent food allergens are highly stable proteins and beyond, impaired gastric digestion and increased intestinal permeability have been associated with clinical food allergy, suggesting particular bioavailability of food antigens in allergic conditions. We hypothesize that immunologically active allergen-derives peptides, circulating in the bloodstream, differ in food-allergic versus food-tolerant individuals. Those allergen peptides signatures, which have never been identified so far, will pave the way for novel personalized medicine approaches in the diagnosis and treatment of food allergies.
Peanut and fish allergies persist usually for lifetime and therefore, are considered as important diseases with high societal impact. In this study, we will recruit up to 30 peanut/fish-allergic patients at the National Service of Immunology-Allergology (CHL), with further patients from collaborators (Denmark, Norway). During food challenges, blood samples will be taken from patients and tolerant controls. Sample storage will be managed at IBBL. Samples will be characteriyed as to the presence of allergen residues (mass spectrometry), antibody patterns (ELISA) and immune cells (basophil activation test, FACS; phenotyping, CyTOF). Finally, clinical data will be integrated at LCSB, together with results from clinical sample analysis to reveal dataset correlations.
Effective start/end date1/01/1830/11/20


  • Personalised Medicine Consortium (PMC): €52,873.00


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.